
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) reported first-quarter 2026 results and used its earnings call to highlight progress across its cell therapy pipeline, including its lead OpRegen program in geographic atrophy, a newly launched corneal endothelial cell program called COR1, and ongoing manufacturing initiatives built around its AlloSCOPE platform.
Chief Executive Officer Brian Culley said the company remains confident in the potential for OpRegen, its retinal pigment epithelium cell transplant program partnered with Roche and Genentech, to advance into a multi-center controlled trial. He noted that Roche and Genentech recently described OpRegen as a potentially disease-modifying treatment, language he characterized as notable because geographic atrophy in dry age-related macular degeneration is a progressive condition.